Electroreduction of CO 2 to multi‐carbon products has attracted considerable attention as it provides an avenue to high‐density renewable energy storage. However, the selectivity and stability under high current densities are rarely reported. Herein, B‐doped Cu (B‐Cu) and B‐Cu‐Zn gas diffusion electrodes (GDE) were developed for highly selective and stable CO 2 conversion to C 2+ products at industrially relevant current densities. The B‐Cu GDE exhibited a high Faradaic efficiency of 79% for C 2+ products formation at a current density of −200 mA·cm ‐2 and a potential of −0.45 V vs. RHE. The long‐term stability for C 2+ formation was substantially improved by incorporating an optimal amount of Zn. Operando Raman spectra confirm the retained Cu + species under CO 2 reduction conditions and the lower overpotential for *OCO formation upon incorporation of Zn, which leads to the excellent conversion of CO 2 to C 2+ products on B‐Cu‐Zn GDEs.
https://ift.tt/3a1Y9pC
A highly active but extremely O2‐sensitive [FeFe] hydrogenase that acts as a H2‐oxidation catalyst in a H2/O2 biofuel cell is integrated in a shielded bioanode and a membrane‐free H2/O2 biofuel cell. The enzyme was wired to gas diffusion electrodes by means of a viologen‐modified redox polymer matrix. Outstanding current densities of up to 14 mA cm−2 and power outputs of 5.5 mW cm−2 in a membrane‐free device were achieved.
Abstract
The incorporation of highly active but also highly sensitive catalysts (e.g. the [FeFe] hydrogenase from Desulfovibrio desulfuricans) in biofuel cells is still one of the major challenges in sustainable energy conversion. We report the fabrication of a dual‐gas diffusion electrode H2/O2 biofuel cell equipped with a [FeFe] hydrogenase/redox polymer‐based high‐current‐density H2‐oxidation bioanode. The bioanodes show benchmark current densities of around 14 mA cm−2 and the corresponding fuel cell tests exhibit a benchmark for a hydrogenase/redox polymer‐based biofuel cell with outstanding power densities of 5.4 mW cm−2 at 0.7 V cell voltage. Furthermore, the highly sensitive [FeFe] hydrogenase is protected against oxygen damage by the redox polymer and can function under 5 % O2.
https://ift.tt/3e29aXa
How do charge carriers move in semi conductors using these two mechanisms
Just a figure to connect the dots would really help me. If anybody knows of any links or even could make a diagram themselves would really help me solve problems when studying for my exam. Thanks!
What happens if I completly compensate the built-in voltage of a pn-junction? There should only be a finite amout of current, due to the finite amout of electrons/holes right?
If anyone has a satisfying answer I would be much obliged.
What?
Diffusion Pharmaceuticals is microcap company working on a drug called [trans sodium crocetinate] or TSC for short. Their primary function is to be used in conjunction with chemo and radiation therapy to stop cancer. Some cancers like Glioblastoma (cancer of the astrocytes--the ones that provide nutrients and oxygen to neurons in the brain) forms a solid mass that prevents neurons from being able to survive. When radiation targets these areas it can be very dangerous because you can't really reproduce new neurons and the therapy is non-discriminate and will kill good and bad cells. This causes a bad reduction in astrocytes and thus less oxygen will be in the brain. What TSC does is raise the efficacy or ability for both the astrocytes and the neurons to better uptake oxygen. This means that there will be better chance for the patient to recovery and if the cancer treatment is successful the brain will be able to build new astrocytes so you don't need to take the drug forever.
Why now?
Currently the company is waiting to start Phase III trials. According to Biopharmacatalyst the company is currently awaiting a strategic partner to commence them. We don't know who this partner will be but we could find out very soon. H.C. Wainwright an investment bank just bought $30 Million Dollars worth of new stock at $1.02. My speculation is that Wainwright invested in the company and they will connect DFFN to one of their other investments and form an alliance to start trials.
They recently did this same thing with Zomedica (A company about to release Truforma a way to test cancer in Dogs and Cats in less than 15 minutes in office.) Zomedica did an offering with them as well EVEN after they released a shareholder letter stating they had secured funding until 2023. So I'm speculating that they did the offering to access the connection of Wainwright so they could find a manufacturing partner, which happened not much longer after the offering.
This institutional investment is great for a young company too because it means that this investment bank needs the company to succeed and will be doing a lot to make it happen.
While I'm not comparing the two companies as equal, Wainwright recently did an offering with Tonix Pharmaceuticals. And, I don't think I need to go on with what happened with that stock. It shot up because they believed in their Covid vaccine and their potential to expand in India and other developing countries as they're making a one
... keep reading on reddit ➡
https://preview.redd.it/vhn9ycgr0ke71.png?width=960&format=png&auto=webp&s=38a83c7853d74ee8142695b976e4cd47295b469d
Hi everyone! I've been trying to export this render, and I'm running into a few issues in using a multi-pass render, particularly in the diffuse/reflection layers. I'm just using the standard renderer here, and in my settings, I have Straight Alpha checked, Anti-Aliasing set to Best, and Filter set to Gauss (Animation).
Just wanted to ask a few questions:
- Why are the reflections and diffuse off-kilter, and how can I fix it?
- How can I render materials in a background object? The gradient was supposed to be a sky in a BG object, but I instead put it as a separate photo in AE
Thanks in advance for the replies! :)
I have seen double diffusing mentioned before (currently only have 1 diffuser), and one time I thought I heard in a video to spray hair with hairspray to “flash dry” it? Is that a thing? I’m tired of going to work with wet hair on wash days so any advice is appreciated! Thanks!
The incorporation of highly active but also highly sensitive catalysts (e.g. the [FeFe] hydrogenase from Desulfovibrio desulfuricans ) in biofuel cells is still one of the major challenges in sustainable energy conversion. We report the fabrication of a dual gas diffusion electrode H 2 /O 2 biofuel cell equipped with a [FeFe] hydrogenase/polymer based high‐current density H 2 oxidation bioanode. The bioanodes show benchmark current densities of around 14 mA cm ‐2 and the corresponding fuel cell tests exhibit a benchmark for a polymer/hydrogenase‐based biofuel cell with outstanding power densities of 5.4 mW cm ‐2 at 0.7 V cell voltage. Furthermore, the highly sensitive [FeFe] hydrogenase is protected against oxygen damage by the redox polymer and can function under 5% O 2 .
https://ift.tt/3e29aXa
What?
Diffusion Pharmaceuticals is microcap company working on a drug called [trans sodium crocetinate] or TSC for short. Their primary function is to be used in conjunction with chemo and radiation therapy to stop cancer. Some cancers like Glioblastoma (cancer of the astrocytes--the ones that provide nutrients and oxygen to neurons in the brain) forms a solid mass that prevents neurons from being able to survive. When radiation targets these areas it can be very dangerous because you can't really reproduce new neurons and the therapy is non-discriminate and will kill good and bad cells. This causes a bad reduction in astrocytes and thus less oxygen will be in the brain. What TSC does is raise the efficacy or ability for both the astrocytes and the neurons to better uptake oxygen. This means that there will be better chance for the patient to recovery and if the cancer treatment is successful the brain will be able to build new astrocytes so you don't need to take the drug forever.
Why now?
Currently the company is waiting to start Phase III trials. According to Biopharmacatalyst the company is currently awaiting a strategic partner to commence them. We don't know who this partner will be but we could find out very soon. H.C. Wainwright an investment bank just bought $30 Million Dollars worth of new stock at $1.02. My speculation is that Wainwright invested in the company and they will connect DFFN to one of their other investments and form an alliance to start trials.
They recently did this same thing with Zomedica (A company about to release Truforma a way to test cancer in Dogs and Cats in less than 15 minutes in office.) Zomedica did an offering with them as well EVEN after they released a shareholder letter stating they had secured funding until 2023. So I'm speculating that they did the offering to access the connection of Wainwright so they could find a manufacturing partner, which happened not much longer after the offering.
This institutional investment is great for a young company too because it means that this investment bank needs the company to succeed and will be doing a lot to make it happen.
While I'm not comparing the two companies as equal, Wainwright recently did an offering with Tonix Pharmaceuticals. And, I don't think I need to go on with what happened with that stock. It shot up because they believed in their Covid vaccine and their potential to expand in India and other developing countries as they're making a one
... keep reading on reddit ➡